Lamivudine
- Product NDC
- 50268-460
- 11-digit product format
- 502680460
- Labeler code
- 50268
- Product ID
- 50268-460_d5ddc7ca-fc7e-c72c-e053-2a95a90a54e7
- Type
- HUMAN PRESCRIPTION DRUG
- Nonproprietary name
- Lamivudine
- Dosage form
- TABLET, FILM COATED
- Route
- ORAL
- Labeler
- AvPAK
- Application
- ANDA203277
- Marketing category
- ANDA
- Marketing start
- 2015-07-30
- Marketing end
- 0000-00-00
- Substance
- LAMIVUDINE
- Active strength
- 300 mg/1
- Pharmacologic classes
- Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC], Nucleoside Reverse Transcriptase Inhibitors [MoA]
- NDC exclude flag
- No
- Listing certified through
- 2023-12-31
- Current FDA listing
- Historical FDA.report record
Packages#
Package NDC, 11-digit format, Description table| Package NDC | 11-digit format | Description | Units | Marketing start | Marketing end | Sample | Exclude flag | Status |
|---|
| 50268-460-13 | 50268046013 | 30 BLISTER PACK in 1 BOX, UNIT-DOSE (50268-460-13) > 1 TABLET, FILM COATED in 1 BLISTER PACK (50268-460-11) | 30 blister pack | 2015-07-30 | 0000-00-00 | No | No | Current |